These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15942701)

  • 21. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P; Torres MJ; Aznar J
    Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae in Japan].
    Yokota S; Sato K; Yoshida S; Fujii N
    Kansenshogaku Zasshi; 2004 May; 78(5):428-34. PubMed ID: 15211865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
    Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
    Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolone resistance in Streptococcus pneumoniae from a university hospital, Thailand.
    Srifuengfung S; Tribuddharat C; Chokephaibulkit K; Comerungsee S
    J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S35-9. PubMed ID: 21298832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The molecular mechanisms of fluoroquinolone resistance found in rectal swab isolates of Enterobacterales from men undergoing a transrectal prostate biopsy: the rationale for targeted prophylaxis.
    Piekarska K; Zacharczuk K; Wołkowicz T; Mokrzyś M; Wolaniuk N; Nowakowska M; Szempliński S; Dobruch J; Gierczyński R
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):81. PubMed ID: 34876123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
    Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
    Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ; Schurek KN; Decorby MR; Weshnoweski B; Vashisht R; Karlowsky K; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2006 Jul; 58(1):202-4. PubMed ID: 16636082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
    Bast DJ; Low DE; Duncan CL; Kilburn L; Mandell LA; Davidson RJ; de Azavedo JC
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3049-54. PubMed ID: 11036021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
    Roychoudhury S; Makin K; Twinem T; Leunk R; Hsu MC
    Microb Drug Resist; 2016 Oct; 22(7):578-584. PubMed ID: 27267788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.
    Nouri R; Ahangarzadeh Rezaee M; Hasani A; Aghazadeh M; Asgharzadeh M
    Braz J Microbiol; 2016; 47(4):925-930. PubMed ID: 27522930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
    Taba H; Kusano N
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
    Jones ME; Sahm DF; Martin N; Scheuring S; Heisig P; Thornsberry C; Köhrer K; Schmitz FJ
    Antimicrob Agents Chemother; 2000 Feb; 44(2):462-6. PubMed ID: 10639387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.
    Zhanel GG; Walkty A; Nichol K; Smith H; Noreddin A; Hoban DJ
    Diagn Microbiol Infect Dis; 2003 Jan; 45(1):63-7. PubMed ID: 12573552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
    De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
    J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
    Nakase K; Sakuma Y; Nakaminami H; Noguchi N
    Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluoroquinolone resistance in Achromobacter spp.: substitutions in QRDRs of GyrA, GyrB, ParC and ParE and implication of the RND efflux system AxyEF-OprN.
    Magallon A; Roussel M; Neuwirth C; Tetu J; Cheiakh AC; Boulet B; Varin V; Urbain V; Bador J; Amoureux L
    J Antimicrob Chemother; 2021 Jan; 76(2):297-304. PubMed ID: 33156919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
    Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
    J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.
    Sunagawa S; Fujita J; Higa F; Tateyama M; Haranaga S; Nakasone I; Yamane N; Uno T
    J Antibiot (Tokyo); 2011 Aug; 64(8):539-45. PubMed ID: 21587266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
    Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
    Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.